TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25190744
Drug: High-Intensity Concurrent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Concurrent Training (HICT) consisting of two weekly sessions of speed endurance training (SET) followed by heavy resistance training (HRT) and two weekly sessions of aerobic training
Study: 25190744
Drug: High-Intensity Concurrent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Concurrent Training (HICT)
Study: 15255784
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (960 micro g d(‐1), 3 months)
Study: 9014483
Drug: Beni-koji aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beni-koji aqueous extracts (27 g of beni-koji eq. per day) for 8 weeks
Study: 1551349
Drug: Metoclopramide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (40 mg/day)
Study: 1551349
Drug: Domperidone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (80 mg/day)
Study: 3924720
Drug: Intravenous nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutritional repletion with dextrose providing 0.95 times baseline resting energy expenditure
Study: 3924720
Drug: Intravenous nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nutritional repletion with dextrose providing 1.75 times baseline resting energy expenditure
Study: 19346114
Drug: Betaine-rich diet
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine-rich diet (approximately 800 mg/day)
Study: 19346114
Drug: Betaine supplement
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine supplement (0.5 g twice daily)
Study: 19346114
Drug: Control (pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-treatment values)
Study: 3323165
Drug: Roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg daily
Study: 3323165
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg bd
Study: 30137297
Drug: Behavioural intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural intervention in pregnancy with online support; Duration: Not specified; Dosage: Not specified
Study: 30137297
Drug: Online support;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online support; Duration: Not specified; Dosage: Not specified
Study: 24095588
Drug: Omega-3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 LCPUFA supplementation (277.8mg DHA and 39.0mg EPA/capsule)
Study: 21782381
Drug: Hydroxypropyl methylcellulose
Normalized name: HYDROXYPROPYL METHYLCELLULOSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropyl methylcellulose (HPMC) 2% gel (Cornea_Protect)
Study: 17065697
Drug: Dietary, drug,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary, drug, and insulin treatments
Study: 15079008
Drug: Cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis extract (oral cannador)
Study: 10075068
Drug: Sufentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (1 microg/kg bolus followed by 0.005 microg/kg/min infusion)
Study: 10075068
Drug: Fentanyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (10 microg/kg bolus followed by 0.075 microg/kg/min infusion)
Study: 10075068
Drug: Alfentanil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (100 microg/kg bolus followed by 0.7 microg/kg/min infusion)
Study: 1828366
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil with continuous epidural infusion of 0.125% bupivacaine
Study: 1828366
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil with continuous intravenous infusion of 0.125% bupivacaine
Study: 6785099
Drug: Intravenously infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously infused saralasin (dose 0.01‐10 microgram kg‐1 min‐1)
Study: 6785099
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of saralasin at the highest dose directly into the renal artery of denervated kidneys
Study: 31586293
Drug: Methimazole (MMI)
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI) 10 mg for 6 weeks prior to 131I therapy
Study: 23783643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ofloxacin (200 mg) and roxithromycin (150 mg) twice daily for 3 months
Study: 23783643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ofloxacin and roxithromycin
Study: 20957498
Drug: mosapride 5
Normalized name: mosapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mosapride 5 mg thrice daily
Study: 11473681
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 0.5 mg twice daily for 1 month followed by 0.25 mg daily for the next 2 months
Study: 11473681
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide 0.1 mg twice daily throughout the 3-month treatment period
Study: 11473681
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (high-dose and low-dose)
Study: 9440663
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir for the prevention of CMV infection
Study: 3263868
Drug: MDP-Lys(L18) 200
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MDP-Lys(L18) 200 micrograms (multiple 5 day administration)
Study: 3263868
Drug: MDP-Lys(L18) (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDP-Lys(L18) (high-dose group)
Study: 5297559
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (for negative reactors)
Study: 5297559
Drug: Smallpox vaccine
Normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smallpox vaccine
Study: 5297559
Drug: Smallpox vaccine
Normalized name: SMALLPOX VACCINE
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smallpox vaccine with BCG for negative reactors
Study: 30093799
Drug: Resonance Voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonance Voice Therapy (RVT)
Study: 30093799
Drug: Cervical-thoracic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical-thoracic therapy
Study: 19914051
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg IV (Group D; n = 30)
Study: 12690049
Drug: Morphine-6-beta-glucuronide (M6G)
Normalized name: TETRAHYDROCURCUMIN .BETA.-O-GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-beta-glucuronide (M6G) infusion (low dose, 2 hours)
Study: 12690049
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion (positive control)
Study: 1345035
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2 g per day)
Study: 31138316
Drug: Continued SDZ
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued SDZ ETN (50 mg subcutaneous once-weekly)
Study: 31138316
Drug: Switched to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched to SDZ ETN (50 mg subcutaneous once-weekly)
Study: 27176631
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with clonidine (15 μg mL-1)
Study: 27176631
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (12.5 μg mL-1)
Study: 23949563
Drug: Standard-volume split-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume split-dose polyethylene glycol with standard diet (SV-PEG with SD)
Study: 19413144
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - sleep education, stimulus control, and time‐in‐bed restrictions; 20 patients with primary insomnia and 21 with comorbid insomnia
Study: 11713064
Drug: Topical fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical fluorometholone (FML) six times daily for 4 weeks (group 1)
Study: 11713064
Drug: Topical fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical fluorometholone (FML) three times daily for 4 weeks (group 2)
Study: 9334554
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of methylphenidate twice per day
Study: 9334554
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of methylphenidate twice per day
Study: 3720365
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine at regular intervals
Study: 3720365
Drug: Subcutaneous nicomorphine
Normalized name: nicomorphine
DrugBank: Nicomorphine (DB13454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous nicomorphine on demand
Study: 25970759
Drug: Topical haemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical haemoglobin spray
Study: 21504072
Drug: Cefixim 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixim 400 mg/day for 5 days
Study: 21504072
Drug: Ciprofloxacin 250‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250‐500 mg twice a day for 5 days
Study: 19352378
Drug: Walnut group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut group (30 g per day walnuts)
Study: 9591737
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 0.4 ng x kg(‐1) x min(‐1)
Study: 9591737
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 1.2 ng x kg(‐1) x min(‐1)
Study: 9591737
Drug: Higher rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher rate of glucagon infusion (1.2 ng x kg(‐1) x min(‐1))
Study: 26965560
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (solifenacin 5 mg + mirabegron 50 mg)
Study: 23084955
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy with adjunctive manual therapy (ET+MT)
Study: 21199294
Drug: Single-dose tenofovir/emtricitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose tenofovir/emtricitabine (TDF/FTC)
Study: 14506195
Drug: 186Re-labeled BIWA
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 186Re-labeled BIWA 4 (bivatuzumab) at doses of 20, 30, 40, 50, and 60 mCi/m2
Study: 10699324
Drug: cpts 248/404
Approvals — FDA: no, EMA: no, PMDA: no
Description: cpts 248/404 RSV vaccine
Study: 10699324
Drug: sequential immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential immunization
Study: 8867548
Drug: Discontinued low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued low dose methotrexate (MTX) prior to and during surgery (Group 1, n = 19)
Study: 8867548
Drug: Continued low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued low dose methotrexate (MTX) throughout the perioperative period (Group 2, n = 13)
Study: 2258342
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of pefloxacin 800 mg
Study: 2258342
Drug: Five-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day treatment with norfloxacin 400 mg twice daily
Study: 6987112
Drug: Rifamycin SV
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifamycin SV by intramuscular injection and topically
Study: 6987112
Drug: Rifamycin SV
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifamycin SV by injection only
Study: 6987112
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment used at the particular centre
Study: 25316715
Drug: t:slim Insulin
Normalized name: t:slim Insulin Delivery System
Approvals — FDA: no, EMA: no, PMDA: no
Description: t:slim Insulin Pump
Study: 25316715
Drug: Revel Insulin
Normalized name: Paradigm Revel Insulin Pump, Blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revel Insulin Pump
Study: 19489765
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Study: 16957638
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 300 mg daily for 3 days, tapered over 1 week
Study: 16957638
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide 10 mg 3 times daily for 1 week
Study: 9525336
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (850 mg/day)
Study: 26310941
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily walking for 30 min)
Study: 24250874
Drug: Carbamazepine (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (300-600 mg/day)
Study: 24250874
Drug: Oxcarbazepine (450-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (450-900 mg/day)
Study: 21353105
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1000 mg q6h
Study: 21353105
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 650 mg q4h
Study: 21353105
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo 100 mL q6h
Study: 21353105
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo 65 mL q4h
Study: 19128627
Drug: Parental guide
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental guide and treatment algorithm
Study: 19128627
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with acetaminophen (15 mg/kg) and morphine (0.3 mg/kg)
Study: 30403954
Drug: Zoliflodacin 2
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin 2 g
Study: 30403954
Drug: Zoliflodacin 3
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin 3 g
Study: 20670400
Drug: HFE homozygous
Normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFE homozygous or compound heterozygous carriers
Study: 12554608
Drug: Cyanamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanamide (200 mg daily)
Study: 8800992
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (500 micrograms delivered over 72 h)
Study: 1738571
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (AT and MT)
Study: 30832590
Drug: CVS as
Normalized name: CVS Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVS as a lightwand (CVS‐L)
Study: 26354593
Drug: Music-with-movement intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-with-movement intervention, developed by a registered music therapist, taught to staff over five weekly 1.5 h sessions.
Study: 22395920
Drug: Bovine intestinal
Normalized name: bovine intestinal mucosa preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine intestinal alkaline phosphatase (bIAP) administered as an intravenous bolus followed by continuous infusion for 36 hours.
Study: 22395920
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as an intravenous bolus followed by continuous infusion for 36 hours.
Study: 18520981
Drug: Creatine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (10 g/d)
Study: 15942183
Drug: Sequential antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antiarrhythmic therapy (propafenone, sotalol, disopyramide) followed by amiodarone if needed
Study: 15942183
Drug: Amiodarone as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone as the third antiarrhythmic agent
Study: 7791815
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (7.5 mg daily for two years)
Study: 28557178
Drug: Antidepressants (imipramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (imipramine, venlafaxine, escitalopram)
Study: 28557178
Drug: Anticonvulsants (pregabalin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsants (pregabalin, oxcarbazepine)
Study: 14576100
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g three times a day)
Study: 14576100
Drug: Imipenem-cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500 mg four times a day)
Study: 8956393
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream for a minimum of 30 minutes
Study: 8956393
Drug: Lidocaine infiltration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infiltration with 3 mL of 1% lidocaine
Study: 4015742
Drug: suprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprofen (200 mg/ml) as i.v. bolus injections
Study: 4015742
Drug: suprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprofen (200 mg/ml) as infusions
Study: 4015742
Drug: suprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprofen (200 mg/ml) as i.v. bolus injections and infusions
Study: 20134408
Drug: Olanzapine (OLZ)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLZ) 5 mg for 3 days then OLZ 10 mg for 12 days
Study: 16410889
Drug: Full set
Normalized name: Silhouette Infusion Full Set-43 inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full set of HBV vaccines
Study: 11185684
Drug: Iodixanol-270 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol-270 (20 ml)
Study: 11185684
Drug: Iopentol-150 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopentol-150 (20 ml)
Study: 19590019
Drug: Active corticosteroid
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active corticosteroid inhaler (quadrupling the dose)
Study: 19590019
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler (no change in corticosteroid dose)
Study: 11870117
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg orally three times a day for 4-6 weeks
Study: 10411763
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 midazolam (n=100)
Study: 10411763
Drug: 1.0 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg.kg‐1 midazolam (n=100)
Study: 10411763
Drug: Intranasal ethyl
Normalized name: Ethyl Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ethyl chloride spray
Study: 10411763
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 midazolam
Study: 10411763
Drug: 1.0 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg.kg‐1 midazolam
Study: 2160379
Drug: Trimethoprim-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin B sulphate cream (0.17 mg/g trimethoprim and 10,000 IU/g polymyxin B sulphate)
Study: 2160379
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid cream (20 mg/g)
Study: 6107292
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No capsule
Study: 25369277
Drug: CoQ10 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (600 mg) daily for 11 days
Study: 11226791
Drug: Cefotaxime 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 0.25% (0.4 mL)
Study: 11226791
Drug: Balanced Salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced Salt Solution (BSS) (control)
Study: 8029191
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid 3 times per week
Study: 8029191
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg folic acid 3 times per week
Study: 8029191
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg folic acid 3 times per week (Control)
Study: 4552464
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets (Control)
Study: 26179754
Drug: Dulaglutide 0.75
Normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.75 mg once-weekly